Residual cohesin function and PARP1 levels determine PARP inhibitor sensitivity in STAG2-deficient cancers
Thom M. Molenaar, Zoi Karagiorgou, S. Jacobs…·Job de Lange
This study identifies residual cohesin function and PARP1 levels as key factors determining PARP inhibitor sensitivity in STAG2-deficient cancers, highlighting the need for biomarker-based patient stratification.